First peer-reviewed results of phase 3 human trials of University of Oxford vaccine demonstrated efficacy
On Dev. 8, 2020, University of Oxford and AstraZeneca researchers present a pooled analysis of Phase 3 trials of a vaccine against SARS-CoV-2 across two different dose regimens, resulting in an average efficacy of 70.4%.
The study published in the Lancet was the first peer-reviewed publication of phase 3 data from studies of a vaccine against the coronavirus.
Tags:
Source: University of Oxford
Credit:
